Source: Agri Pulse
In this opinion piece, American Veterinary Medical Association President Michael Bailey urges Congress to pass the bipartisan Combating Illicit Xylazine Act to address the growing misuse of xylazine in the illicit fentanyl supply while preserving its essential Veterinary uses. Although the fentanyl-xylazine combination is a serious public health threat, xylazine itself is a critical FDA-approved sedative widely used by veterinarians, farmers and ranchers, particularly for cattle, horses and wildlife.
Bailey warns that if the Drug Enforcement Administration schedules xylazine without necessary statutory changes, increased regulatory burdens could disrupt supply or drive manufacturers out of the low-margin market, leaving veterinarians without a vital tool. The proposed legislation would classify xylazine as a Schedule III drug while protecting legitimate Veterinary access and improving federal oversight. Supported by law enforcement groups and Veterinary organizations nationwide, the bill aims to balance combating illicit use with safeguarding animal welfare and public health.